Tiansheng Pharmaceutical Group Past Earnings Performance
Past criteria checks 0/6
Tiansheng Pharmaceutical Group's earnings have been declining at an average annual rate of -7.8%, while the Pharmaceuticals industry saw earnings growing at 9.6% annually. Revenues have been declining at an average rate of 31% per year.
Key information
-7.8%
Earnings growth rate
-6.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -31.0% |
| Return on equity | -5.2% |
| Net Margin | -18.0% |
| Next Earnings Update | 27 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tiansheng Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 609 | -110 | 358 | 35 |
| 31 Mar 23 | 629 | -91 | 380 | 35 |
| 31 Dec 22 | 607 | -91 | 393 | 34 |
| 30 Sep 22 | 540 | -63 | 327 | 28 |
| 30 Jun 22 | 512 | -74 | 296 | 30 |
| 31 Mar 22 | 538 | -58 | 320 | 30 |
| 01 Jan 22 | 737 | -68 | 346 | 29 |
| 30 Sep 21 | 904 | -439 | 423 | 27 |
| 30 Jun 21 | 1,088 | -463 | 455 | 26 |
| 31 Mar 21 | 1,245 | -508 | 470 | 25 |
| 31 Dec 20 | 1,203 | -491 | 443 | 22 |
| 30 Sep 20 | 1,312 | -279 | 524 | 32 |
| 30 Jun 20 | 1,411 | -298 | 587 | 31 |
| 31 Mar 20 | 1,497 | -242 | 564 | 35 |
| 31 Dec 19 | 1,680 | -224 | 560 | 36 |
| 30 Sep 19 | 1,760 | -201 | 612 | 28 |
| 30 Jun 19 | 1,861 | -95 | 540 | 30 |
| 31 Mar 19 | 2,025 | -47 | 514 | 38 |
| 31 Dec 18 | 2,171 | 9 | 504 | 40 |
| 30 Sep 18 | 2,328 | 234 | 343 | 36 |
| 30 Jun 18 | 2,346 | 255 | 300 | 59 |
| 31 Mar 18 | 2,348 | 258 | 335 | 42 |
| 31 Dec 17 | 2,261 | 247 | 323 | 34 |
| 30 Sep 17 | 2,228 | 241 | 310 | 30 |
| 30 Jun 17 | 2,192 | 236 | 334 | 0 |
| 31 Mar 17 | 2,131 | 231 | 374 | 0 |
| 31 Dec 16 | 2,087 | 224 | 302 | 0 |
| 31 Dec 15 | 1,843 | 192 | 256 | 0 |
| 31 Dec 14 | 1,664 | 165 | 225 | 0 |
| 31 Dec 13 | 1,422 | 126 | 220 | 0 |
Quality Earnings: 002872 is currently unprofitable.
Growing Profit Margin: 002872 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002872 is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare 002872's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002872 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 002872 has a negative Return on Equity (-5.24%), as it is currently unprofitable.